Zolmitriptan reverses blink reflex changes induced during the migraine attack in humans
- 1 July 2000
- journal article
- Published by Elsevier in Neuroscience Letters
- Vol. 289 (1) , 57-60
- https://doi.org/10.1016/s0304-3940(00)01255-6
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Pre-clinical pharmacology of zolmitriptan (Zomig™; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraineCephalalgia, 1997
- Zolmitriptan (Zomig™, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: An overview of efficacyCephalalgia, 1997
- Peripheral and Central Trigeminovascular Activation in Cat is Blocked by the Serotonin (5HT)‐I D Receptor Agonist 311C90Headache: The Journal of Head and Face Pain, 1994
- Inhibition by sumatriptan of central trigeminal neurones only after blood‐brain barrier disruptionBritish Journal of Pharmacology, 1993
- Nociceptive quality of the orbicularis oculi reflexes as evaluated by distinct opiate- and benzodiazepine-induced changes in manBrain Research, 1991
- Guidelines for Controlled Trials of Drugs in Migraine. First EditionCephalalgia, 1991
- Preclinical Studies on the Anti-Migraine Drug, SumatriptanEuropean Neurology, 1991
- Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular systemAnnals of Neurology, 1988